Fact sheet | 31 January 2025 First Trust NYSE Arca FBTAccAccEURUSD Biotechnology UCITS ETF ISIN IE00BL0L0H60 Thematic The Fund is a passively managed index-tracking fund that seeks to provide investors Asset Class Equity with investment results that correspond generally to the price and yield of the NYSE Arca Fund Inception 27.05.2020 Biotechnology IndexSM , (the “Index”), before fees and expenses. The modified equally- weighted index is designed to measure the performance of a cross section of companies in theShare Class Inception27.05.2020 biotechnology industry that are primarily involved in the use of biological processes to develop Ongoing Charges1 0.60% products or provide services. Base CurrencyUSD Income Treatment AccumulatingPerformance Total Fund AUM $8.87 millionThe figures shown relate to past performance and do not predict future returnsPerformance Since Inception (%) Outstanding Shares 400,002 n Acc USD 15 UCITS Compliant Yes 10 Domicile Ireland 5 Investment Manager First Trust Advisors 0 -5 Rebalance Frequency Quarterly -10 Replication Method Physical - -15 Full Replication -20 -25 SFDR Classification Article 6 Jul 2 0Apr 2 1 Ja n 2 2 Oct 2 2 Jul 2 3 Apr 2 4 Ja n 2 5 Tracking Index NYSE® Arca Biotechnology Index SincePerformance Summary (%) 1M 3M YTD 1Y 3Y 5 Y InceptionRISK AND REWARD PROFILE Acc USD8.99 7.258.99 22.14 6.81 - 2.23 1 2 3 4 5 6 7Lower risk Higher riskTracking Index 9.07 7.409.07 22.87 7.46 - 2.74Potentially lower rewards Potentially higher rewardsPerformance for periods under one year is cumulative and over one year is annualised.The Synthetic Risk and Reward Indicator (SRRI) 31.12.19 31.12.20 31.12.21 31.12.22 31.12.23illustrates a fund’s risk and reward profile througha number between 1 and 7.12-Month Performance Periods (%) 31.12.20 31.12.21 31.12.22 31.12.23 31.12.24 Acc USD - ‑3.70 ‑4.70 2.23 5.55 Trading InformationTracking Index - ‑3.61 ‑4.12 2.79 6.21 ExchangeCcy TickerSEDOLLondon Stock Exchange GBP FBT LN BLBPQX5 Fund performance is the performance of the share class since its inception, shown net of fees including re- London Stock Exchange USD FBTU LN BJYFRJ1invested dividends in the base currency of the share class which is in USD. Performance can go up as well asBorsa Italiana EURFBT IM BLCWGQ8down, and investors may lose some or all of their capital. Returns may increase or decrease as a result of currencyand exchange rate fluctuations. Please refer to the 'Risks' section on Page 3 for more details on risks associatedwith an investment in the fund. The share class was launched less than 5 years ago, therefore performance for ISA SIPP UK Reporting Statussome periods is not available.1 The ongoing charges figure is based on the Fund's annual management fee, whereby the Investment Manageris responsible for the costs involved in running the Fund. In the event that the Fund's running costs exceedthe stated figure the Investment Manager shall pay the excess from its own assets. The ongoing charges figureexcludes portfolio transaction costs. Details of the transaction costs are available from your broker or financialadvisor and at www.ftgportfolios.com. The figure may vary from year to year. First Trust NYSE Arca Biotechnology UCITS ETF- -Data as at 31 January 2025 Portfolion The index is reconstituted and TOP 10 HOLDINGS (%) rebalanced quarterly in January, April, Top 10 Holdings as % of TotalJuly and October. Corcept Therapeutics Inc. 4.24n The securities selected for inclusion in Intra-Cellular Therapies, Inc. 4.23 the index are equally weighted. Index BeiGene, Ltd. (ADR) 4.02 composition changes during scheduled reconstitutions are also subject to certain Alnylam Pharmaceuticals, Inc. 3.60 37.12% buffers designed to limit turnover Mettler-Toledo International Inc. 3.57 n The highest ranked 30 securities are Vertex Pharmaceuticals Incorporated 3.56 62.88% selected for inclusion in the index. i. Additionally, the total number of index Alkermes Plc 3.55 constituents classified to the Biotech Veracyte, Inc. 3.46 Tools & Diagnostics sub-industry is capped at 6 constituents. If the limit is Waters Corporation 3.45 reached, the lowest ranked Biotech Tools Amgen Inc. 3.44 & Diagnostics constituents are replaced with the next highest ranked Biotech Top 10 holdings as a percentage of Total Net Assets. Portfolio Holdings are subject to change at any time. References to Therapeutics non-constituents until this specific securities should not be construed as a recommendation to buy or sell and should not be assumed profitable. rule is met.n Eligible securities are then ranked in descending order based on the following factors. These three distinct ranks are then SECTOR ALLOCATION (%)combined to yield one comprehensive rank based on their respective weights: Health Care 100.00 i. 50%: Net sales (revenue) over the last 12 months, ii. 25%: Ratio of net sales (revenue) to R&D (research and development) expenditures over the last 12 months, COUNTRY ALLOCATION (%) FUND CHARACTERISTICS iii. 25%: Percentage change in R&D 🇺🇸 United States 79.70 expenditures (over the last 12 months) 🇰🇾 Max Market Cap $153.4bn from those three years prior. Cayman Islands 4.03Median Market Cap $15.3bn n To be included in the index, a common 🇨🇭 Switzerland 3.57Min Market Cap $3.1bn stock or depositary receipt must be listed 🇮🇪 on a qualifying U.S. securities exchange, Ireland 3.55 4.25 Price/Book and meet the size and liquidity standards 🇩🇪 Germany 3.18Price/Cash Flow 24.51 of the index 🇳🇱 The Netherlands 3.16Price/Sales 5.59n The industryBiotechnologygroupsub- includes: 🇩🇰 Denmark 2.81 Index Yield 0.23% i. The Biotech Therapeutics Sub-Industry: Companies engaged in the research and development of therapeutic treatments (including companies in the trial phase of therapeutic development), but are not focused on the commercialisation and mass production of pharmaceutical drugs, ii. The Biotech Tools & Diagnostics Sub-Industry: Companies engaged in the production and provisioning of tools, systems or processes that enable biotechnology practices (including companies that provide assaying equipment, sequencing techniques or systems, DNA processing, or cellular processing).n The NYSE® Arca® Biotechnology Index is an equal dollar-weighted index designed to measure the performance of 30 leading biotechnology companies classified within the Biotechnology sub- industry group of the ICE Uniform Sector Classification schema. Page 2 of 3 First Trust NYSE Arca Biotechnology UCITS ETF- -Data as at 31 January 2025Risks n The Fund may not achieve its investment objective and the value of shares development costs required to bring a drug to market are substantial and in the Fund may fall. may include a lengthy review by the government, with no guarantee that n Neither First Trust Global Portfolios Management Limited (“FTGPM”) nor any of the product will ever be brought to market or show a profit. Many of these its affiliates, guarantees the performance or the future returns of the Fund. companies may not offer certain drugs or products for several years, and as a result, may have significant losses of revenue and earnings. n The Fund invests in biotechnology and pharmaceutical companies, which are subject to changing government regulation which could have a negative n There is no assurance that the Index will continue to be calculated and published effect on the price, profitability and availability of their products and services. on the basis described in the Prospectus. In addition, the Fund’s return may not Biotechnology and pharmaceutical companies face increasing competition match the return of the Index. from generic drugs, termination of their patent protection and technological n See also the description of the risks applicable to the Fund in “Risk Factors” in advances which render their products or services obsolete. The research and the Prospectus. Important Information UK RETAILftglobalportfolios.com to obtain the Fund's prospectus, supplement and KIID. This marketing communication is issued by First Trust Global Portfolios Investors and potential investors can obtain a summary in English of investor Management Limited (“FTGPM”) whose place of business is Fitzwilliam Hall,rights and information on access to collective redress mechanisms in the event Fitzwilliam Place, Dublin 2, D02 T292. FTGPM is authorised and regulated by the of litigation at the following website: https://www.ftglobalportfolios.com/ Central Bank of Ireland (“CBI”) (C185737). The Fund is also regulated by the CBI.Content/SUMMARY_OF_INVESTOR_RIGHTS. Nothing contained herein constitutes investment, legal, tax or other advice and The Fund is currently notified for marketing into a number of EU Member States it is not to be solely relied on in making an investment or other decision, nor under the UCITS Directive. The Company may however decide to terminate the does the document implicitly or explicitly recommend or suggest an investmentarrangements made for the marketing of any share class of the Fund at any time strategy, reach conclusions in relation to an investment strategy for the reader, or using the process contained in the UCITS Directive. provide any opinions as to the present or future value or price of any fund. It is not Any UCITS ETF’s units / shares purchased on the secondary market cannot usually an invitation, offer, or solicitation to engage in any investment activity, includingbe sold directly back to UCITS ETF. Investors must buy and sell units / shares on a making an investment in the Fund, nor does the information, recommendations secondary market with the assistance of an intermediary (e.g. a stockbroker) and or opinions expressed herein constitute an offer for sale of the Fund. may incur fees for doing so. In addition, investors may pay more than the current The Fund is an open-ended sub-fund of First Trust Global Funds PLC (the net asset value when buying units / shares and may receive less than the current “Company”), an umbrella UCITS fund with segregated liability between sub-net asset value when selling them. funds, incorporated with limited liability as an investment company with variableThe Company’s portfolio holdings policy is designed to be transparent, whilst capital under the laws of Ireland with UCITS registered number 514357. being in the best interest of the Fund and protecting the confidentiality of each The material in this marketing communication is not comprehensive and must Fund’s portfolio holdings. The full portfolio holdings for the Fund shall generally therefore be read in conjunction with the Fund’s prospectus, the relevantbe available daily, with a one-day lag, on www.ftglobalportfolios.com. Any supplement, and the UCITS key investor information document (“KIID”) which portfolio holdings information which may otherwise be provided on request contains material information not contained herein, including the terms shall be provided on a confidential basis. of investment and information regarding investment risks and restrictions, NYSE and NYSE® Arca Biotechnology Index are service/trademarks of ICE Data fees and expenses and conflicts of interests. Potential investors should pay Indices, LLC or its affiliates (“IDI”) and have been licensed for use by First Trust particular attention to the risk disclosures in the “Risk Factors” section of thein connection with the Fund. The Fund is not sponsored, endorsed, sold or Fund’s prospectus and supplement (available in English) and KIIDs (available promoted by IDI and IDI makes no representations or warranties regarding for each share class of each of the sub-funds of the Company and in one of the the advisability of investing in the Fund or as to the result to be obtained by official languages of each of the EU Member States into which each sub-fund any person from use of the Index in connection with the trading of the Fund. has been notified for marketing under the Directive 2009/65/EC (the UCITSIDI and its third party suppliers accept no liability in connection with use of Directive)). No assurance can be given that the Fund’s investment objective will the index or the Fund. See the prospectus for a full copy of the disclaimer. be achieved or that the Fund will generate a positive return. Please contact First Trust Global Portfolios Limited (“FTGP”), the distributor of the Fund, or visit www. Page 3 of 3